BlackRock’s Ventyx Biosciences VTYX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-3,142,440
| Closed | -$28.4M | – | 5803 |
|
|
2025
Q4 | $28.4M | Buy |
3,142,440
+1,959,200
| +166% | +$14.6M | ﹤0.01% | 2878 |
|
|
2025
Q3 | $3.68M | Sell |
1,183,240
-184,765
| -14% | -$490K | ﹤0.01% | 3905 |
|
|
2025
Q2 | $2.93M | Sell |
1,368,005
-3,071,260
| -69% | -$4.96M | ﹤0.01% | 3956 |
|
|
2025
Q1 | $5.11M | Sell |
4,439,265
-62,457
| -1% | -$107K | ﹤0.01% | 3640 |
|
|
2024
Q4 | $9.86M | Sell |
4,501,722
-409,675
| -8% | -$928K | ﹤0.01% | 3440 |
|
|
2024
Q3 | $10.7M | Buy |
4,911,397
+139,740
| +3% | +$321K | ﹤0.01% | 3365 |
|
|
2024
Q2 | $11M | Buy |
4,771,657
+1,024,564
| +27% | +$4.26M | ﹤0.01% | 3335 |
|
|
2024
Q1 | $20.6M | Sell |
3,747,093
-67,438
| -2% | -$308K | ﹤0.01% | 2983 |
|
|
2023
Q4 | $9.42M | Buy |
3,814,531
+186,311
| +5% | +$1.77M | ﹤0.01% | 3426 |
|
|
2023
Q3 | $126M | Buy |
3,628,220
+401,648
| +12% | +$13.9M | ﹤0.01% | 1855 |
|
|
2023
Q2 | $106M | Buy |
3,226,572
+1,177,971
| +58% | +$40.6M | ﹤0.01% | 2009 |
|
|
2023
Q1 | $68.6M | Buy |
2,048,601
+78,738
| +4% | +$3.06M | ﹤0.01% | 2250 |
|
|
2022
Q4 | $64.6M | Buy |
1,969,863
+588,360
| +43% | +$17.4M | ﹤0.01% | 2290 |
|
|
2022
Q3 | $48.2M | Buy |
1,381,503
+324,314
| +31% | +$7.18M | ﹤0.01% | 2459 |
|
|
2022
Q2 | $12.9M | Buy |
1,057,189
+565,853
| +115% | +$8.46M | ﹤0.01% | 3366 |
|
|
2022
Q1 | $6.67M | Sell |
491,336
-3,366
| -0.7% | -$45K | ﹤0.01% | 3796 |
|
|
2021
Q4 | $9.83M | Buy |
+494,702
| New | +$9.38M | ﹤0.01% | 3685 |
|
Other funds holding VTYX
BlackRock's VTYX Position: Q1 2026 in Review
BlackRock sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 3,142,440 shares — an estimated $28.4M sold.
BlackRock first reported a position in VTYX in Q4 2021 and held it in 17 quarters. The position peaked at $126M in Q3 2023. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.
- BlackRock reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
- BlackRock sold 3,142,440 Ventyx Biosciences shares in Q1 2026, an estimated $28.4M.
- BlackRock first reported a position in Ventyx Biosciences in Q4 2021 and held it in 17 quarters.
- BlackRock's Ventyx Biosciences position peaked at $126M in Q3 2023.
- 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.
Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.